Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'

• Judith M Versluis,
• Daniela S Thommen

Affiliations

Judith M Versluis

Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Daniela S Thommen

Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands